Methotrexate Adjuvants to Reduce Toxicity and Methods for Using the Same
US RE48,253 In forceTerm ends Mar 5, 2029 · Low confidence
20-year base term ends Mar 2, 2029
Reissue of US 9,382,287, which was surrendered when this reissue was granted; its term and maintenance fees continue here.
Mar 2, 2009
Mar 5, 2029
Oct 13, 2020
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Mar 2, 2009, when the earliest non-provisional application in its chain was filed (this one was filed Jun 29, 2018) | Mar 2, 2029 | High confidence |
| Continuity chain | A reissue: its term follows the original patent's, with the original's term adjustment | follows the original patent | Medium confidence |
| Patent term adjustment | +3 days, the original patent's USPTO patent term adjustment record, which governs a reissue (35 U.S.C. 251). This reissue's own record carries none | Mar 5, 2029 | Medium confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Mar 5, 2029 | Low confidence |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Not on this page: the patent's family, its recorded assignments and its citation count. USPTO's assignment records, linked above, list every recorded assignment.
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.